Page last updated: 2024-11-12
epelsiban
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
epelsiban: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11634973 |
| CHEMBL ID | 2037511 |
| CHEBI ID | 177448 |
| SCHEMBL ID | 1597672 |
| MeSH ID | M0572512 |
Synonyms (35)
| Synonym |
|---|
| 872599-83-2 |
| CHEBI:177448 |
| epelsiban |
| (3r,6r)-6-[(2s)-butan-2-yl]-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethylpyridin-3-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione |
| D10117 |
| epelsiban (usan) |
| bdbm50384820 |
| 3-(2,3-dihydro-1h-inden-2-yl)-1-(1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl)-6-(1-methylpropyl)-2,5-piperazinedione |
| (3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin- 4-yl)-2-oxoethyl)-6-((1s)-1-methylpropyl)piperazine-2,5-dione |
| 2,5-piperazinedione, 3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2,6-dimethyl-3-pyridinyl)- 2-(4-morpholinyl)-2-oxoethyl)-6-((1s)-1-methylpropyl)-, (3r,6r)- |
| unii-t2ez19hx73 |
| epelsiban [usan:inn] |
| t2ez19hx73 , |
| gsk 557296 |
| gsk557296 |
| CHEMBL2037511 |
| gsk-557296 |
| epelsiban [who-dd] |
| 3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoethyl)-6-((1s)-1-methylpropyl)piperazine-2,5-dione |
| 2,5-piperazinedione, 3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl)-6-((1s)-1-methylpropyl)-, (3r,6r)- |
| epelsiban [usan] |
| (3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-((1r)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoethyl)-6-((2s)-butan-2-yl)piperazine-2,5-dione |
| morpholine, 4-((2r)-((3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-6-((1s)-1-methylpropyl)-2,5-dioxo-1-piperazinyl)(2,6-dimethyl-3-pyridinyl)acetyl)- |
| epelsiban [inn] |
| SCHEMBL1597672 |
| UWHCWRQFNKUYCG-QUZACWSFSA-N |
| (3r,6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione |
| HY-105018 |
| CS-0024708 |
| DB11934 |
| Q5382095 |
| (3r,6r)-6-((s)-sec-butyl)-3-(2,3-dihydro-1h-inden-2-yl)-1-((r)-1-(2,6-dimethylpyridin-3-yl)-2-morpholino-2-oxoethyl)piperazine-2,5-dione |
| 872599-83-2 (free base) |
| DTXSID701029864 |
| AKOS040733331 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Headache was the most common adverse event, and rates were similar across all groups." | ( Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study. Barnes, A; Black, L; Condreay, LD; Giancaterino, L; Mahar, KM; McCallum, SW; Shinghal, R; Stier, B, 2013) | 0.7 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats." | ( Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. Allen, MJ; Borthwick, AD; Davies, DE; Exall, AM; Hamlett, C; Hickey, DM; Liddle, J; Mason, AM; Nerozzi, F; Peace, S; Pollard, D; Pullen, MA; Smith, IE; Sollis, SL; Stanislaus, DJ; Westfall, TD; Woollard, PM, 2012) | 1.29 |
Dosage Studied
Epelsiban was generally well tolerated. No events of clinical concern were observed in volunteers dosed in this study.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Epelsiban was generally well tolerated, and no events of clinical concern were observed in volunteers dosed in this study." | ( A single- and multiple-dose study to investigate the pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteers. Fries, M; Mahar, KM; McCallum, SW; Stier, B, 2015) | 1.56 |
| " In 1 study (n = 12), epelsiban was dosed at 300 or 450 mg twice daily (every 12 hours) for a single day." | ( Single- and Multiple-Day Dosing Studies to Investigate High-Dose Pharmacokinetics of Epelsiban and Its Metabolite, GSK2395448, in Healthy Female Volunteers. Amrine-Madsen, H; Cooper, M; Enslin, MB; Gress, A; Mahar, KM, 2018) | 1.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (9)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7740 | 10.0000 | AID664091 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0001 | 1.7536 | 10.0000 | AID664095; AID664096 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.0151 | 10.0000 | AID664094 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.8005 | 10.0000 | AID664092 |
| Vasopressin V2 receptor | Homo sapiens (human) | Ki | 3.9811 | 0.0004 | 0.4345 | 3.9811 | AID664086 |
| Oxytocin receptor | Homo sapiens (human) | IC50 (µMol) | 0.0092 | 0.0027 | 0.2191 | 0.5190 | AID1568181 |
| Oxytocin receptor | Homo sapiens (human) | Ki | 0.0001 | 0.0001 | 0.0718 | 0.9780 | AID664068 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.3983 | 10.0000 | AID664093 |
| Vasopressin V1a receptor | Homo sapiens (human) | Ki | 6.3096 | 0.0002 | 0.6235 | 7.0300 | AID664084 |
| Vasopressin V1b receptor | Homo sapiens (human) | Ki | 7.9433 | 0.0005 | 0.1897 | 1.7820 | AID664085 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (111)
Molecular Functions (40)
Ceullar Components (15)
Bioassays (43)
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 23.75
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.75) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (42.86%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||